The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Neurol.
Sec. Movement Disorders
Volume 16 - 2025 |
doi: 10.3389/fneur.2025.1500766
This article is part of the Research Topic Life with Tic Disorders: From Childhood to Adulthood View all articles
Relationships Between the Menstrual Cycle and Neuropsychiatric and Physical Symptoms in Females with Tourette Syndrome
Provisionally accepted- 1 Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
- 2 Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Maryland, United States
- 3 Department of Psychiatry, College of Medicine, University of Florida, Gainsville, Florida, United States
- 4 Genetics Institute, University of Florida, Gainesville, Alabama, United States
- 5 Center for OCD, Anxiety, & Related Disorders, Department of Psychiatry, College of Medicine, University of Florida, Gainesville, Florida, United States
- 6 Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
- 7 Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
- 8 Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
Background: The effects of the menstrual cycle on neuropsychiatric and physical symptoms have been examined in multiple psychiatric illnesses, but research on Tourette syndrome (TS) and menstruation is limited and inconclusive. One study published in 1992 reported that 34% of female respondents experienced tic fluctuations with their menstrual cycles; however, a subsequent 2001 study found no significant relationship between menstrual cycle-related hormonal changes and tic symptoms across participants. There has been no further published exploration of this topic in the intervening 20+ years, and thus these discrepant results have not been reconciled. The current study aimed to assess tic changes across the menstrual cycle and to explore clinical predictors of tic fluctuations in adult females with TS. Methods: An online survey was completed by 112 of 315 eligible female adults with TS. Respondents were asked to share their age of TS symptom onset, history of OCD and ADHD diagnoses, and current tic symptoms and severity. Participants also retrospectively reported their experiences with fluctuations in tics and other physical and psychiatric symptoms over the course of the menstrual cycle. Results: 26% of the 112 respondents endorsed tic changes in relation to their menstrual cycles. Univariable and multivariable logistic regression demonstrated that higher current tic severity and impairment as well as co-occurring cycle-related mood and anxiety changes significantly predicted the presence of self-reported tic fluctuations during the menstrual cycle. Discussion: Results suggest that some females with TS experience changes in tic symptoms during their menstrual cycles, although future research is required to clarify the complex relationships between the menstrual cycle, tics, and other psychiatric symptoms. The low response rate, retrospective recall of symptoms, and lack of information about hormonal influences such as contraceptives and menopause are notable study limitations.
Keywords: Tourette Syndrome, Tic Disorders, tic fluctuations, Menstrual Cycle, female, sex hormones, Neurosteroids, Allopregnanolone
Received: 23 Sep 2024; Accepted: 09 Jan 2025.
Copyright: © 2025 Noriega, Realbuto, Kaylor, Osiecki, Essa, Yu, Illmann, Mathews and Scharf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Evan Realbuto, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
Lisa Osiecki, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
Angela Essa, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
Dongmei Yu, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
Cornelia Illmann, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
Jeremiah M Scharf, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.